Rani Therapeutics Holdings posts net loss of $31.9 million for Q3 2025

Reuters
2025.11.06 21:44
portai
I'm PortAI, I can summarize articles.

Rani Therapeutics Holdings Inc. reported a net loss of $31.9 million for the nine months ended September 30, 2025, a 22% decrease from a net loss of $40.9 million in the same period of 2024. The net loss attributable to the company was $19.4 million, down 8.1% from $21.1 million the previous year. Contract revenue was $0.2 million, attributed to an agreement with Chugai, compared to no revenue in 2024. The company is focused on developing its oral delivery technology and pursuing partnerships with biopharmaceutical firms.

Rani Therapeutics Holdings Inc. reported a net loss of $31.9 million for the nine months ended September 30, 2025, compared to a net loss of $40.9 million for the same period in 2024, representing a decrease of 22.0%. Net loss attributable to Rani Therapeutics Holdings Inc. was $19.4 million, down 8.1% from $21.1 million in the prior year period. Contract revenue was $0.2 million for the nine months ended September 30, 2025, attributed to evaluation services under an agreement with Chugai, while there was no contract revenue in the same period of 2024. The company continued to focus on developing its proprietary oral delivery technology for biologics and drugs and pursued partnerships with biopharmaceutical firms for the oral delivery of their products. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rani Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-269774), on November 06, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here

Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.